

Velcade® (bortezomib) - First-time generic

- On May 2, 2022, AuroMedics, Baxter Healthcare, Zydus, <u>Sagent Pharmaceuticals</u>, <u>Apotex</u>, <u>Gland Pharma</u>, <u>Aurobindo/Eugia</u> and <u>Fresenius Kabi launched</u> AP-rated generic versions of Takeda's <u>Velcade (bortezomib)</u> injection.
 - In addition, <u>Teva</u> received FDA approval of AP-rated generic Velcade on May 2, 2022.
 The launch date for this generic manufacturer is pending.
- Velcade is approved for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
- According to IQVIA, Velcade had U.S. sales of ~\$1.2 billion for the 12 months ending March 2022.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.